The 100,000 Genomes Club
10 Countries Meet the Mark for National Genome Projects
Vertex’s David Altshuler Humanizes Drug Discovery
Lessons from Vertex’s Small Molecule Drug Development Program for Cystic Fibrosis
GEN Roundup: Multiplexed Immunoassays: Small Samples, Big Pictures
Taking in "Everything All at Once" Can Reveal Meaningful Biological Patterns and Drug Targets
Brexit’s Effect on U.K. Life Sciences
Making the Nation a One-Stop Regulatory Engine for Innovation
For full access to this article login to GEN Select now.
Novel ADMET Technologies Gain Traction
- Too many new drug compounds fail in late-stage clinical trials due to inefficacy and safety concerns. With often-cited costs of $800 million to bring a new drug to market, a compelling need exists for improved early-stage screening. Insufficient knowledge of potential human toxicity can turn a promising lead candidate ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.